Vor Biopharma (NYSE:VOR – Get Rating)‘s stock had its “initiates” rating reissued by equities research analysts at Wedbush in a research report issued to clients and investors on Tuesday, Benzinga reports. Wedbush also issued estimates for Vor Biopharma’s Q2 2022 earnings at ($0.72) EPS, Q3 2022 earnings at ($0.60) EPS, Q4 2022 earnings at ($0.67) EPS, FY2022 earnings at ($2.59) EPS, FY2023 earnings at ($2.98) EPS, FY2024 earnings at ($2.86) EPS, FY2025 earnings at ($2.89) EPS and FY2026 earnings at ($2.34) EPS.
Several other equities analysts have also recently weighed in on VOR. HC Wainwright reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Vor Biopharma in a report on Monday, May 16th. The Goldman Sachs Group started coverage on Vor Biopharma in a report on Wednesday, April 27th. They issued a “neutral” rating and a $6.00 target price for the company. Finally, JMP Securities reduced their price target on Vor Biopharma from $30.00 to $15.00 in a research report on Friday, May 13th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Vor Biopharma presently has a consensus rating of “Moderate Buy” and an average price target of $25.63.
Vor Biopharma Stock Performance
Vor Biopharma stock traded down $0.20 during midday trading on Tuesday, reaching $4.80. The stock had a trading volume of 220 shares, compared to its average volume of 113,313. The stock has a market capitalization of $180.05 million, a P/E ratio of -2.25 and a beta of -1.01. Vor Biopharma has a 1-year low of $3.83 and a 1-year high of $18.51. The firm’s fifty day simple moving average is $4.88 and its 200-day simple moving average is $6.43.
Institutional Trading of Vor Biopharma
A number of institutional investors and hedge funds have recently modified their holdings of VOR. Ergoteles LLC purchased a new stake in shares of Vor Biopharma during the first quarter valued at approximately $97,000. Bourgeon Capital Management LLC increased its position in shares of Vor Biopharma by 75.1% during the fourth quarter. Bourgeon Capital Management LLC now owns 10,600 shares of the company’s stock valued at $123,000 after acquiring an additional 4,547 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of Vor Biopharma by 36.4% during the fourth quarter. New York State Common Retirement Fund now owns 10,649 shares of the company’s stock valued at $124,000 after acquiring an additional 2,843 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Vor Biopharma by 48.6% during the first quarter. Goldman Sachs Group Inc. now owns 25,607 shares of the company’s stock valued at $155,000 after acquiring an additional 8,370 shares during the last quarter. Finally, Virtus ETF Advisers LLC grew its holdings in Vor Biopharma by 39.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 13,311 shares of the company’s stock valued at $155,000 after purchasing an additional 3,778 shares during the period. 83.11% of the stock is owned by hedge funds and other institutional investors.
About Vor Biopharma
Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
- Get a free copy of the StockNews.com research report on Vor Biopharma (VOR)
- Ford Stock Rallies As EV Strategy Takes Center Stage
- Should High Yield Altria Be In Your Portfolio?
- Is Keurig-Dr. Pepper A Value Worth Buying?
- C3.AI Stock is a Bargain Enterprise Artificial Intelligence Game Changer
- Did The FOMC Put A Bottom In The S&P 500?
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.